Scarica l'app Stockscreener
0.319
12.91%
-0.0473
Dopo l'orario di chiusura:
.32
0.001
+0.31%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Jaguar Health’s Napo unit advances MVID trial toward 2027 filing - Investing.com
Jaguar Health advances crofelemer MVID pediatric trial - grafa.com
Jaguar Health Stock Slides Thursday: What's Happening? - Benzinga
JAGX Looks 99.7% Undervalued on GF Value™ but Faces Price-to-Sales Challenges - GuruFocus
Jaguar Health’s Napo unit advances MVID trial toward 2027 filing By Investing.com - Investing.com India
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) - Yahoo! Finance Canada
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise - Yahoo Finance
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs - ACCESS Newswire
Amazon now carries a plant-based product for dogs with loose stools - Stock Titan
Jaguar Health Faces Shareholder Quorum Challenge at Meeting - tipranks.com
Jaguar Health calls special meeting but fails to achieve quorum; no votes taken - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Jaguar Health progresses crofelemer for rare intestinal failure disorders - The Pharma Letter
Jaguar Animal Health Inc (JAGX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
JAGX Looks 99.4% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Jaguar Health plans MVID drug application for mid-2027 By Investing.com - Investing.com Australia
Jaguar Health plans MVID drug application for mid-2027 - Investing.com
News by ACCESS Newswire on TradingView, 2026-09-04 - TradingView
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) - Yahoo Finance
Jaguar Health presents crofelemer data at ESPGHAN 2026 - scanx.trade
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
Jaguar Health launches Neonorm Dog for digestive support By Investing.com - Investing.com Canada
News by ACCESS Newswire on TradingView, 2026-08-26 - tradingview.com
Jaguar Health launches Neonorm Dog for digestive support - Investing.com
Jaguar Health: Sales And Marketing Spending Reduced More Than 99% After Future Pak Licensing Deal - Pulse 2.0
Form 424B3 Jaguar Health, Inc. - StreetInsider
Jaguar (JAGX) Latest: Finishes 1.74% Down at $0.86; Market Levels: Traders Can Monitor the $0.82-$0.90 Range for the Current SessionEarnings Miss Risk - vinanet.vn
Jaguar Health | 424B3: Prospectus - Moomoo
Jaguar Health revenue falls 59% to $1.2 million - grafa.com
Jaguar Health | 10-Q: Quarterly report - Moomoo
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and Strategic Pivot - GuruFocus
Jaguar Health (JAGX) Shifts Focus to Rare GI Treatments Amid Cha - GuruFocus
Jaguar Health Sets Q2 2027 NDA Submission Timeline for MVID Treatment - Minichart
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Jaguar Health Posts Q2 Total Revenue $1.2 Million, EPS $-15.68 - TradingView
Jaguar Health Q2 loss narrows 96% as revenue falls 59% on licensing shift - scanx.trade
Q2 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Reports $1.2 Million Q2 Revenue and $12.7 Million Net Loss - Quiver Quantitative
Jaguar Health Reports Second Quarter 2026 Financials - ACCESS Newswire
Jaguar Health to hold Q2 2026 investor webcast on August 19 - scanx.trade
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates - Yahoo Finance
JAGX Q2'26 Earnings: EPS estimate is (52.15) USD - TradingView
Jaguar Health, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Jaguar Health Delays Quarterly SEC Filing - TipRanks
Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan
Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan
Jaguar Health (JAGX) Ticks Up 2.22% to $0.96, Approaching Key Resistance at $1.01Systematic Flow - vinanet.vn
Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus
Why is Jaguar Health stock gaining today? - Investing.com
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-05 - TradingView
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeRVOL Spike - vinanet.vn
Jaguar Health (JAGX) Holds at $1.00 as Tight Trading Range Defines Key Levels to WatchInstitutional Buy Signals - vinanet.vn
JAGX Q1 2026 Earnings: EPS Misses Estimates by 553.6%, Shares Gain 7.63%Earnings Turnaround - vinanet.vn
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada
Almost 80% of Vet Oncologists Would Recommend Neonorm Dog - Stock Titan
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):